Ascendis Pharma A/S expected to post earnings of €1.38 a share - Earnings Preview

Ascendis Pharma A/S

11/08/2026 13:32

Ascendis Pharma A/S ASND.OQ ASND.O is expected to  show a rise in quarterly revenue when it reports  results on August 13 for the period ending June 30 2026
The Hellerup Capital Region Of Denmark-based  company is expected to report a 109.8% increase in revenue to €331.56 million from €158.05 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Ascendis Pharma A/S is for earnings of €1.38 per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 20 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Ascendis Pharma A/S is $305.50, about 19.5% above its last closing price of $255.62
Previous quarterly performance (using preferred earnings measure in euros). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
0.15
0.20
-0.77
Missed
-478.6
Dec. 31 2026
-0.04
-0.04
-0.55
Missed
-1,122.2
Sep. 30 2025
-0.08
-0.22
-1.00
Missed
-354.5​
Jun. 30 2025
-1.17
-1.25
-0.64
Beat
48.7
​​Mar. 31 2025
-1.49
-1.49
-1.58
Missed
-5.8
Dec. 31 2024
-0.84
-0.96
-0.64
Beat
33.2​
Sep. 30 2024
-1.76
-1.74
-1.72
Beat
1.2
Jun. 30 2024
-1.34
-1.38
-1.91
Missed
-38.1
This summary was machine generated August 11 at 12:32 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)